JAGX Stock Overview
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea.
Jaguar Health Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.17|
|52 Week High||US$2.66|
|52 Week Low||US$0.15|
|1 Month Change||-28.90%|
|3 Month Change||-47.94%|
|1 Year Change||-92.56%|
|3 Year Change||-95.33%|
|5 Year Change||-99.97%|
|Change since IPO||-99.99%|
Recent News & Updates
Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront
Jaguar Health (NASDAQ:JAGX) announced Tuesday the sale of certain royalty rights to Utah-based Streeterville Capital for $4M consideration. The rights relate to future crofelemer and lechlemer revenue stream and some other up-front license fees, excluding any fees due to Jaguar from its crofelemer license for the European territory to its recently established Italian corporation - Napo Therapeutics - and will pay interest on the royalty payment amount at a rate of 10% annual until the same is paid in full. This transaction follows two royalty-based deals Jaguar executed in 2020, both of which also involved allocating proceeds to progress the company's ongoing Phase 3 pivotal OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea. "The commercial-stage pharmaceutical company is focused on concentrating its resources to two key development which includes "the completion of enrollment during the first half of 2023 for the OnTarget trial and the completion in 2022 of an investigator-initiated proof-of-concept study of crofelemer for short bowel syndrome, supporting the potential for reimbursed expanded patient access through programs in Europe in 2023," commented Lisa Conte, Jaguar's president and CEO. Shares are up 3% in premarket on Thursday to trade at $0.24 vs. 52-week range of $0.22 to $3.75
Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule
Jaguar Health (NASDAQ:JAGX) has been granted an additional 180-day grace period to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, the pharmaceuticals company announced on Friday. The company must report a closing bid price of at least $1.00/share for a minimum of ten consecutive business days on or before Feb. 13, 2023 to show compliance. Speaking on the news, CEO Lisa Conte said, "Jaguar is focused on two late-stage clinical events in the next approximately 6 to 12 months that we expect to be transformational in terms of value creation and recognition for the company as we seek to regain compliance with the rule." An investigator-initiated proof-of-concept study of crofelemer for short bowel syndrome (SBS) is anticipated to complete in 2022. The second key clinical activity is Jaguar's Phase 3 pivotal OnTarget trial of crofelemer for its core follow-on indication of prophylaxis of cancer therapy-related diarrhea. The company expects enrollment in this trial to complete in the first half of 2023.
Jaguar Health rises on U.S. patent for treating chemotherapy-induced diarrhea
Jaguar Health (NASDAQ:JAGX) said the United States Patent and Trademark Office had issued a new U.S. patent to its subsidiary, Napo Pharmaceuticals, for methods for treating diarrhea, as well as the pain, abdominal discomfort and other symptoms associated with diarrhea, in patients with an inhibitor of chloride-ion transport such as Napo's crofelemer drug product. (JAGX) has risen 6.2%. The company's crofelemer drug product candidate is in ongoing Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy.
|JAGX||US Pharmaceuticals||US Market|
Return vs Industry: JAGX underperformed the US Pharmaceuticals industry which returned 2.9% over the past year.
Return vs Market: JAGX underperformed the US Market which returned -23.1% over the past year.
|JAGX Average Weekly Movement||10.0%|
|Pharmaceuticals Industry Average Movement||11.6%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: JAGX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: JAGX's weekly volatility (10%) has been stable over the past year.
About the Company
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Jaguar Health Fundamentals Summary
|JAGX fundamental statistics|
Is JAGX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|JAGX income statement (TTM)|
|Cost of Revenue||US$2.00m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.45|
|Net Profit Margin||-652.41%|
How did JAGX perform over the long term?See historical performance and comparison
Is JAGX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for JAGX?
Other financial metrics that can be useful for relative valuation.
|What is JAGX's n/a Ratio?|
Price to Sales Ratio vs Peers
How does JAGX's PS Ratio compare to its peers?
|JAGX PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
JUVA.F Juva Life
CLVR Clever Leaves Holdings
GNRS Greenrose Holding
JAGX Jaguar Health
Price-To-Sales vs Peers: JAGX is expensive based on its Price-To-Sales Ratio (2.4x) compared to the peer average (1.3x).
Price to Earnings Ratio vs Industry
How does JAGX's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Sales vs Industry: JAGX is good value based on its Price-To-Sales Ratio (2.4x) compared to the US Pharmaceuticals industry average (2.8x)
Price to Sales Ratio vs Fair Ratio
What is JAGX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||2.4x|
|Fair PS Ratio||11.3x|
Price-To-Sales vs Fair Ratio: JAGX is good value based on its Price-To-Sales Ratio (2.4x) compared to the estimated Fair Price-To-Sales Ratio (11.3x).
Share Price vs Fair Value
What is the Fair Price of JAGX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: JAGX ($0.17) is trading below our estimate of fair value ($36.34)
Significantly Below Fair Value: JAGX is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Jaguar Health forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JAGX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: JAGX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: JAGX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: JAGX's revenue (46.2% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: JAGX's revenue (46.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if JAGX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Jaguar Health performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: JAGX is currently unprofitable.
Growing Profit Margin: JAGX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: JAGX is unprofitable, and losses have increased over the past 5 years at a rate of 19.5% per year.
Accelerating Growth: Unable to compare JAGX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JAGX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).
Return on Equity
High ROE: JAGX has a negative Return on Equity (-1960.97%), as it is currently unprofitable.
Discover strong past performing companies
How is Jaguar Health's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: JAGX's short term assets ($23.4M) exceed its short term liabilities ($22.9M).
Long Term Liabilities: JAGX's short term assets ($23.4M) do not cover its long term liabilities ($24.2M).
Debt to Equity History and Analysis
Debt Level: JAGX's net debt to equity ratio (808.8%) is considered high.
Reducing Debt: JAGX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: JAGX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: JAGX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 15.7% each year
Discover healthy companies
What is Jaguar Health current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate JAGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate JAGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if JAGX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if JAGX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as JAGX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Lisa Conte (63 yo)
Ms. Lisa A. Conte serves as a Scientific Advisor at Triton Funds LLC. She is a Former Member of Scientific Advisory Board at Triton Funds LLC. She founded Jaguar Health, Inc. (formerly known as Jaguar Anim...
CEO Compensation Analysis
Compensation vs Market: Lisa's total compensation ($USD1.89M) is above average for companies of similar size in the US market ($USD780.01K).
Compensation vs Earnings: Lisa's compensation has increased whilst the company is unprofitable.
Experienced Management: JAGX's management team is considered experienced (2.5 years average tenure).
Experienced Board: JAGX's board of directors are considered experienced (5.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 160.1%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Jaguar Health, Inc.'s employee growth, exchange listings and data sources
- Name: Jaguar Health, Inc.
- Ticker: JAGX
- Exchange: NasdaqCM
- Founded: 2013
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$19.969m
- Shares outstanding: 119.86m
- Website: https://jaguar.health
Number of Employees
- Jaguar Health, Inc.
- 200 Pine Street
- Suite 400
- San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|JAGX||NasdaqCM (Nasdaq Capital Market)||Yes||Voting Common Stock||US||USD||Aug 2017|
|1JA||DB (Deutsche Boerse AG)||Yes||Voting Common Stock||DE||EUR||Aug 2017|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/24 00:00|
|End of Day Share Price||2022/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.